Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SL-1002 is a novel, chemoneurolytic injection, that utilizes Saol's proprietary CYCLOPHLEX™ technology, which is investigated for the treatment of Osteoarthritis Knee Pain.
Lead Product(s): SL-1002
Therapeutic Area: Musculoskeletal Product Name: SL-1002
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Dichloroacetate (SL-1009) has the potential to be the 1st approved medication for the mitochondrial disease PDCD. DCA inhibits PDKs to stimulate residual PDC activity and increase energy (ATP) production by mitochondria.
Lead Product(s): Dichloroacetic Acid
Therapeutic Area: Rare Diseases and Disorders Product Name: SL-1009
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Amneal is adding Saol’s experienced institutional commercial team for Lioresal that can be utilized to support product launches, including biosimilar products, filgrastim (biosimilar for Neupogen), pegfilgrastim (biosimilar for Neulasta) & bevacizumab (biosimilar for Avastin).
Lead Product(s): Baclofen
Therapeutic Area: Musculoskeletal Product Name: Lioresal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 05, 2022
Details:
Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Lead Product(s): Cytomegalovirus Immune Globulin [Human],Ganciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Cytogam
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kamada
Deal Size: $145.0 million Upfront Cash: $95.0 million
Deal Type: Acquisition November 22, 2021